Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyGlobeNewsWire • Thursday
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 MillionGlobeNewsWire • Thursday
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewsWire • 02/13/24
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyGlobeNewsWire • 11/30/23
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/17/23
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewsWire • 11/13/23
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 09/21/23
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public OfferingGlobeNewsWire • 08/11/23
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public OfferingGlobeNewsWire • 08/09/23
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023GlobeNewsWire • 07/25/23
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyGlobeNewsWire • 06/26/23
Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 05/15/23
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 02/13/23
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development ProgramGlobeNewsWire • 01/23/23
Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 11/10/22
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public OfferingGlobeNewsWire • 09/16/22
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public OfferingGlobeNewsWire • 09/13/22
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational UpdateGlobeNewsWire • 09/02/22
Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial ResultsPRNewsWire • 09/20/21
Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment ConferencePRNewsWire • 09/13/21